Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues.
OBJECTIVE
To explore the inhibition of beta-L-D4A on hepatitis B virus (HBV) in 2.2.15 cells derived from HepG2 cells transfected with HBV genome.


METHODS
2.2.15 cells were plated at a density of 5X104 per well in 12-well tissue culture plates, and treated with various concentrations of beta-L-D4A for 6 days. In the end, 5 microl of medium was used for the estimation of HBsAg and HBeAg, the other medium was processed to obtain virions by a polyethylene glycol precipitation method. At the same time, intracellular DNA was also extracted and digested with HindIII. Both DNAs were subjected to Southern blot, hybridized with a (32)P-labeled HBV probe and autoradiographed. Intensity of the autoradiographic bands was quantitated by densitometric scans of computer and ED(50) was calculated. Then Hybond-N membrane was washed and rehybridized with a (32)P-labeled mtDNA-specific probe, and effect of beta-L-D4A on mitochondrial DNA was studied. 2.2.15 cells were also seeded in 24-well tissue culture plates, and cytotoxicity with different concentrations was examined by MTT method. ID(50) was calculated. Structure-activity relationships between D2A and D4A were also studied as above.


RESULTS
Autoradiographic bands were similar between supernatant and intracellular HBV DNA. Episomal HBV DNA was inhibited in a dose-dependent manner. ED(50) was 0.2 microM. HBsAg or HBeAg was not apparently decreased, and inhibition of mitochondrial DNA was not obvious. The experiment of cytotoxicity gained ID(50) at 200 microM.


CONCLUSIONS
beta-L-D4A possesses potent inhibitory effects on the replication of HBV in vitro with little cytotoxicity and mitochondrial toxicity, TI value is 1000. It is expected to be developed as a new clinically anti-HBV drug.
Wu
Jin-Ming
JM
Institute of Liver Diseases, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Lin
Ju-Sheng
JS
Xie
Na
N
Liang
Kuo-Huan
KH
D016048:Dideoxyadenosine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006514:Hepatitis B Surface Antigens / Q000187:drug effects; D006513:Hepatitis B e Antigens / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D014779:Virus Replication / Q000187:drug effects
D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016048:Dideoxyadenosine; C075923:2'3'-didehydro-2'3'-dideoxyadenosine